Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report

. 2014 May 21;2014:371087. doi: 10.1155/2014/371087

(a)

qPCR primer sequence
RASSF1A	Forward	5′-GCTGAGCGTCACGGCCAAGT-3′ 5′-ATGCTGAAGGCGTCCCAGTT-3′
RASSF1A	Reverse	5′-GCTGAGCGTCACGGCCAAGT-3′ 5′-ATGCTGAAGGCGTCCCAGTT-3′

MAGEA-1	Forward	5′-TCCGCCTTTCCCACTACCAT-3′ 5′-TCCAGCATTTCTGCCTTTGT-3′
MAGEA-1	Reverse	5′-TCCGCCTTTCCCACTACCAT-3′ 5′-TCCAGCATTTCTGCCTTTGT-3′

MAGEA-3	Forward	5′-GGAGTCCGAGTTCCAAGCAG-3′ 5′-AGGCAGGTGGCAAAGATGTA-3′
MAGEA-3	Reverse	5′-GGAGTCCGAGTTCCAAGCAG-3′ 5′-AGGCAGGTGGCAAAGATGTA-3′

P15	Forward	5′-CAACGGAGTCAACCGTTTCGG-3′ 5′-CAGCACCACCAGCGTGTCCAG-3′
P15	Reverse	5′-CAACGGAGTCAACCGTTTCGG-3′ 5′-CAGCACCACCAGCGTGTCCAG-3′

p16	Forward	5′-CTGGACACGCTGGTGGTGCT-3′ 5′-CTATGCGGGCATGGTTACTGC-3′
p16	Reverse	5′-CTGGACACGCTGGTGGTGCT-3′ 5′-CTATGCGGGCATGGTTACTGC-3′

BRCA1	Forward	5′-AGAAACCACCAAGGTCCAAA-3′ 5′-CCAAGGGTGAATGATGAAAG-3′
BRCA1	Reverse	5′-AGAAACCACCAAGGTCCAAA-3′ 5′-CCAAGGGTGAATGATGAAAG-3′

β-Actin	Forward	5′-AAAGACCTGTACGCCAACAC-3′ 5′-GTCATACTCCTGCTTGCTGAT-3′
β-Actin	Reverse	5′-AAAGACCTGTACGCCAACAC-3′ 5′-GTCATACTCCTGCTTGCTGAT-3′